- Report
- February 2024
- 175 Pages
Global
From €4797EUR$5,000USD£4,148GBP
- Report
- October 2023
- 190 Pages
Global
From €4701EUR$4,900USD£4,065GBP
- Report
- June 2022
- 259 Pages
Global
From €3056EUR$3,185USD£2,643GBP
€4366EUR$4,550USD£3,775GBP
- Report
- June 2022
- 117 Pages
Global
From €4558EUR$4,750USD£3,941GBP
- Report
- February 2022
- 308 Pages
Global
From €9115EUR$9,500USD£7,882GBP
- Newsletter
- May 2024
- 14 Pages
United Kingdom
- Newsletter
- May 2024
- 14 Pages
United States
- Report
- September 2018
- 630 Pages
Global
From €21109EUR$22,000USD£18,253GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €480EUR$500USD£415GBP
- Report
- January 2019
- 35 Pages
Global
From €959EUR$1,000USD£830GBP
- Report
- April 2022
- 131 Pages
Global
From €1919EUR$2,000USD£1,659GBP
Lonsurf is a type of colon cancer drug used to treat metastatic colorectal cancer. It is a combination of two active ingredients, trifluridine and tipiracil hydrochloride, which work together to inhibit the growth of cancer cells. The drug is administered orally and is available in tablet form. It is used in combination with other chemotherapy drugs to treat metastatic colorectal cancer that has progressed after treatment with other chemotherapy drugs.
Lonsurf is approved by the US Food and Drug Administration (FDA) and is available in many countries around the world. It is also approved for use in the European Union and Japan.
The Lonsurf market is highly competitive, with many companies offering similar products. Some of the major players in the market include Taiho Pharmaceutical, Merck & Co., Pfizer, and AstraZeneca. Other companies in the market include Bristol-Myers Squibb, Novartis, and Eli Lilly. Show Less Read more
